Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance BoostInvestors Business Daily • 10/28/22
Dassault Systèmes Partners with Sanofi to Optimize Tech Transfer and Industrialization at Its Future “EVolutive Facilities”Business Wire • 10/26/22
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years oldGlobeNewsWire • 10/11/22
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetesPRNewsWire • 10/06/22
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularisGlobeNewsWire • 09/28/22
BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASDBusiness Wire • 09/19/22
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infantsGlobeNewsWire • 09/16/22
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularisGlobeNewsWire • 09/08/22
Sanofi (SNY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)Seeking Alpha • 09/07/22
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthmaGlobeNewsWire • 09/05/22